Stock to Buy: Pharma Stock With 31% Upside Potential

Synopsis: Natco Pharma has gained attention after Investec reiterated a Buy rating with a ₹1,220 target, implying 31% upside. The optimism is driven by strong core earnings, diversification beyond gRevlimid, semaglutide growth potential, global launches, a robust cash position, and improved FY27–FY28 earnings estimates.

The shares of a Small-Cap company specialising in the development, manufacturing, and commercialisation of complex, niche pharmaceutical generics are in focus following the brokerage firm Investec’s target, which sees 31 percent upside potential.

With a market capitalization of Rs. 16,820.21 crores in the day’s trade, the shares of Natco Pharma Ltd rose by 2.1 percent, reaching a high of Rs. 953.30 per share compared to its previous closing price of Rs. 933.20 per share.

What Happened 

Natco Pharma Ltd, engaged in the development, manufacturing, and commercialisation of complex, niche pharmaceutical generics, is in the spotlight as brokerage firm Investec maintains a Buy target price of Rs. 1220, implying about 31 percent upside from the previous close price of Rs. 933.20. Reason for the Target:

Strong Core Business Performance

Q4 results were healthy despite a one-off expense impacting reported earnings. Adjusting for this exceptional item, the core business showed strong operational execution, indicating that the company’s underlying profitability and business momentum remain intact and stronger than headline numbers suggest.

Robust Earnings Without gRevlimid Contribution

Natco delivered a solid quarterly performance even without a meaningful contribution from gRevlimid revenues. This demonstrates the strength and diversification of its existing product portfolio, reducing dependence on a single high-value opportunity and supporting sustainable long-term earnings growth.

Semaglutide Opportunity in India

The India semaglutide business is expected to become a significant growth driver, with potential sales of around ₹1 billion. Rising demand for diabetes and obesity treatments creates a favourable market environment, positioning Natco to benefit from an attractive and expanding therapeutic segment.

New Product Launches Across Key Markets

Recent and upcoming launches in Brazil, Canada, and the US provide multiple growth avenues. Geographic diversification enhances revenue visibility, reduces dependence on any single market, and supports stronger earnings growth through an expanding international product pipeline.

Strong Cash Position Enables Strategic Flexibility

With approximately Rs. 2,500 crore in cash, Natco has substantial financial strength. The balance sheet provides flexibility for acquisitions, licensing deals, capacity expansion, or other growth initiatives, while management’s conservative capital allocation approach helps limit execution and financial risks.

Upgraded Earnings Outlook Supports Higher Valuation

Investec raised FY27 and FY28 EPS estimates by 5% and 4%, respectively, reflecting improved confidence in future growth drivers. Higher earnings expectations typically justify a higher valuation multiple, supporting the increased target price of Rs. 1,220 from the earlier Rs. 1,035.

Financials & Others

The company’s revenue declined by 39.47 percent from Rs. 1,221 crores in March 2025 to Rs. 1,221 crores in March 2026. Meanwhile, Net profit declined from Rs. 406 crores to Rs. 269 crores in the same period.

The company shows strong profitability metrics, with ROCE at 17.1% and ROE at 16.9%, indicating efficient use of capital and solid returns for shareholders. Its low debt-to-equity ratio of 0.08 reflects a very conservative and financially stable balance sheet.

Valuation appears attractive, with a stock P/E of 11.7 significantly below the industry P/E of 30.8. A PEG ratio of 0.44 further suggests the stock may be undervalued relative to its growth. Fundamentally, the company has delivered a strong 5-year profit CAGR of 27.7%, highlighting consistent earnings growth and strong operational performance.

The revenue breakup (%) for Q4 FY26 of the company shows that Export Formulation is the dominant contributor at 66%, followed by Domestic Formulation at 17%. The remaining share is contributed by Others (10.1%), API (7.8%), and Crop Health Sciences (2.8%), indicating a strong dependence on export-led revenues in the quarter.

For FY26 overall, the reliance on exports is even higher at 73.9%. Domestic Formulation contributes 10.1%, while Others, API, and Crop Health Sciences account for 7.5%, 5.4%, and 3.2%, respectively. Compared to Q4, FY26 shows a slightly more export-heavy and consolidated revenue structure.

Natco Pharma Ltd is an Indian multinational pharmaceutical company headquartered in Hyderabad, India. It focuses on developing and manufacturing complex generic medicines, especially in niche and high-barrier segments like oncology, cardiology, and speciality therapies. The company is known for its strong research-driven approach and for producing affordable versions of expensive patented drugs for global markets.

It operates across three main segments: finished dosage formulations (generic medicines), active pharmaceutical ingredients (APIs), and contract manufacturing. Natco exports to more than 50 countries, including the US and Europe, and has built a reputation for challenging drug patents and launching cost-effective generics in regulated markets.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Stock to Buy: Pharma Stock With 31% Upside Potential appeared first on Trade Brains.